经皮肝穿刺无水酒精瘤内注射治疗原发性小肝癌的意义

Percutaneous ethanol intratumoral injection for treatment of small primary liver cancer: Summary of 240 cases

Objective To evaluate the therapeutic effects of percutaneous ethanol intratumoral injection (PEIT) for treatment of small primary liver cancer (SPLC). Methods 240 patients with surgically or pathologically proved SPLC (<3 cm in diameter) were treated by PEIT (under the guidance of B-ultrasound). Of the 240 patients, 163 had recurrent liver cancer, 55 had inoperable liver cancer because of cardiac, pulmonary, hepatic and renal dysfunctions or due to the close proximity of tumor to the major vessels, and 22 refused to receive surgical resection. In 40 patients who received surgical resection after PEIT treatment, the resected tumors were pathologically evaluated for necrotic status and the patients were followed up postoperatively. Results Postoperative 1-, 2- and 3-year survival rate of the 240 patients was 94.9%, 84.2% and 66.3% respectively. Conclusion PEIT can be used as a non-invasive treatment for SPLC, and preoperative PEIT appears to be helpful in reducing recurrence of postoperative liver cancer.